L'intérêt à découvert pour Revolution Medicines donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Revolution Medicines. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Revolution Medicines (NASDAQ:RVMD) Stock, Rapport sur les intérêts à découvert

REVOLUTION MEDICINES INC

Revolution Medicines

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines, Inc. - Common Stock

Revolution Medicines Inc

Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File
Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of AD04 for US Clinical Trials And NDA Submission
GLEN ALLEN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the recent execution of agreements for the production of AD04 (0.33 mg ondansetron tablets), supporting both the completion of upcoming clinical trials and the planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for the treatment of Alcohol Use Disorder (AUD) in the US. AD04 is the Company's lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of AUD in heavy drinking patients.
The strategic collaboration with Thermo Fisher Scientific as the Contract Development and Manufacturing Organization (CDMO) for AD04 Drug Product, and Cambrex, a drug substance CDMO and supplier of Ondansetron API, has begun and is already seeing results in completion of the demonstration batches required prior to the conduct of the registration and clinical batches. The importance of choosing CDMOs with both drug substance development and manufacturing capabilities with successful track records was a key element to the signing of the agreements. The agreements include all phases of manufacturing for both the clinical supplies needed to conduct the upcoming clinical studies for AD04, as well as the Chemistry, Manufacturing, and Controls (CMC) module documentation required for the submission of the NDA to the FDA.

News

ADIL

Adial Pharma Secures AD04 Production Agreements Ahead Of NDA Filing; Scope Of Agreement With Cambrex To Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File

Shares of Becton Dickinson and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until early June 2027. Here's a breakdown of why the stock's structure looks weak under the lens of the Adhishthana Principles, our proprietary cyclical framework combining behavioral archetypes, timing structures, and quantitative signals.
<h3 class="wp-block-heading">BDX's Alignment So Far &amp; The 1400 Days of Consolidation</h3>
BDX began its Adhishthana Cycle on a strong note, showing consistent alignment with the framework during the early phases. However, a critical shift occurred as the stock entered Phase 8.
According to the Adhishthana Principles, a stock begins forming its Cakra from Phase 4, with the formation typically concluding by Phase 8. The Cakra, often a bullish arc-like structure, represents the preparation for a potential breakout in Phase 9.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="607" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana.png" alt="Fig.1 BDX Cakra Breakdown (Source: Adhishthana.com)" class="wp-image-14855" style="width:686px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana-300x152.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana-1024x518.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080431/BDX-Weekly-Cakra-Breakdown-Adhishthana-768x388.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 BDX Cakra Breakdown (Source: Adhishthana.com)</figcaption></figure>
In BDX's case, the Cakra formation broke down in Phase 8, a major deviation from the ideal path. Rather than respecting the lower arc of the Cakra and preparing for a breakout, BDX broke beneath it, signaling a shift into prolonged weakness and stalling bullish momentum.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"When the underlying breaks the Cākra on the flip side, it typically draws consolidation up to the Guna triads." — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="371" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana.png" alt="Fig.2 BDX's Consolidation (Source: Adhishthana.com)" class="wp-image-14861" style="width:760px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana-300x93.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana-1024x317.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080630/BDX-Consolidation-Adhishthana-768x237.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.2 BDX&#8217;s Consolidation (Source: Adhishthana.com)</figcaption></figure>
True to this principle, BDX remained in a sideways consolidation for over 1,400 days, validating this structural breakdown.
<h3 class="wp-block-heading">The Guna Triads: A Major Red Flag</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="874" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana.png" alt="Fig.3 BDX's Guna Triads (Source: Adhishthana.com)" class="wp-image-14856" style="width:575px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana-300x219.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana-1024x746.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080518/BDX-Guna-Triads-Adhishthana-768x559.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.3 BDX&#8217;s Guna Triads (Source: Adhishthana.com)</figcaption></figure>
Phases 14, 15, and 16 in the Adhishthana framework are known as the Guna Triads. The triads determine whether a stock is capable of attaining Nirvana in Phase 18, which is the highest price point in its cycle.
BDX's triads were one of the weakest among peer stocks. They showed no signs of Satoguna, the essence of a clean and decisive bullish move. Instead, the structure appeared disjointed, with low momentum and unclear direction. This lack of energy suggests that Phase 18 will not result in a new high, and the stock is likely to remain in a corrective or consolidative mode until the cycle ends on 6 June 2027.&nbsp;
<h3 class="wp-block-heading">Monthly Chart Outlook: More Consolidation Ahead</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="587" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart-.png" alt="Fig.4 BDX's Monthly Chart (Source: Adhishthana.com)" class="wp-image-14859" style="width:633px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart-.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart--300x147.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart--1024x501.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/25080555/BDX-Adhishthana-Monthly-Chart--768x376.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.4 BDX&#8217;s Monthly Chart (Source: Adhishthana.com)</figcaption></figure>
On the monthly timeframe, BDX is currently in the Sankhya Period of Phase 2, typically characterized by bearish pressure and range-bound behavior. This phase extends until 2 August 2027, reinforcing the view that the stock is unlikely to gain significant bullish momentum in the near term.
<h3 class="wp-block-heading">Investor Takeaway: Avoid the Trap</h3>
The structural breakdown of the Cakra in Phase 8, coupled with weak Guna Triads and a bearish Sankhya move on the monthly charts, all point to one thing: BDX is not yet ready for a recovery yet. The stock's internal structure reflects deeper issues, possibly ethical or fundamental, and any rallies are likely to be short-lived traps.
Until the Adhishthana cycle realigns and shows strength in the later phases, investors are better off staying away from BDX. Long-term recovery isn't on the cards until after mid-2027 and that too only if stronger signs appear in the next cycle.

Equities

Technicals

Opinion

Signals

Trading Ideas

Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now

RSLS

ReShape Lifesciences Granted Patent In Australia For Its Diabetes Neuromodulation Technology

WIIM

PONY

Pony AI shares are trading higher after the company announced it has been added to the Nasdaq Golden Dragon China Index.

As Microsoft tightens access to its Bing Search APIs, privacy-focused search engine Presearch has launched a decentralized search API aimed at providing developers with a censorship-resistant and transparent alternative.
Backed by more than 40,000 active nodes, Presearch's new API is designed to serve as an open access tool for developers seeking privacy-first search solutions amid increasing restrictions from major providers.
The Presearch Search API operates on a decentralized infrastructure, offering fast, low-latency search results without user profiling or centralized control. 
The API supports pay-as-you-go pricing in Bitcoin, Circle&#8216;s USDC, Presearch's native PRE token, or fiat, and is accessible via Presearch's gateway system, which strips all personally identifiable information from user queries.
The launch arrives as developers face shrinking options for integrating search data. 
Microsoft's API shutdowns and pricing hikes have reportedly forced thousands of developers to find new solutions, with over 50,000 apps estimated to have lost reliable search access since early 2024, according to a press release shared with Benzinga.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46080751/anthony-pomplianos-procap-buys-over-3700-bitcoin-whats-driving-the-aggressive-bet">Anthony Pompliano&#8217;s ProCap Buys Over 3,700 Bitcoin—What&#8217;s Driving The Aggressive Bet?</a>
Presearch's decentralized system uses a blend of Proof-of-Work and Proof-of-Stake models. 
Node operators contribute compute power, stake PRE tokens, and earn rewards based on search demand. 
According to the company, the infrastructure remained operational during a significant Big Tech outage in 2023, underscoring the resilience of its decentralized model.
The platform has attracted a growing user base, with over 390,000 active monthly users and more than 400,000 daily searches. Presearch also powers search-driven applications like Scout.click, which adopted the Presearch API after losing access to traditional providers.
Presearch CEO Tim Enneking said the platform's mission aligns with the core principles of decentralization and freedom of information. 
"We believe freedom of information is just as important as freedom of money," he said.
The company's roadmap includes enabling Bitcoin payments, expanding developer integrations, and continuing to grow its decentralized node network to meet demand from developers building AI, productivity, and content applications.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46077689/polymarket-reportedly-looking-to-raise-200-million-at-1b-valuation">Polymarket Reportedly Looking To Raise $200 Million At $1B Valuation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

As Bing Goes Private, Presearch Opens Censorship-Resistant Search API For Developers

Earnings

Earnings Misses

PAYX

Paychex Q4 Adj. EPS $1.19, Inline, Sales $1.427B Miss $1.436B Estimate

&#x2A;Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market
Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease
NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) and Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) today announced the formation of a strategic joint venture to develop and commercialize a first-in-class treatment for obesity and metabolic disease based on technology exclusively licensed from the U.S. Department of Veterans Affairs (VA).
The novel therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.
Deal Highlights:
<ul>
<li>Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use</li>
<li>50/50 Joint Venture structure with equal equity and governance participation&nbsp;</li>
<li>Lead Indication: Obesity and NAFLD&nbsp;</li>
</ul>

HOTH

SILO

Hoth Therapeutics And Silo Pharma Form Strategic JV To Develop, Commercialize Treatment For Obesity, Metabolic Disease Based On Technology Exclusively Licensed From U.S. Department Of Veterans Affairs

Worthington Enterprises shares are trading higher after the company reported better-than-expected Q4 financial results.

General Mills shares are trading lower after the company reported mixed Q4 financial results and issued weak FY26 adjusted guidance.

BTIG analyst Thomas Catherwood maintains Hudson Pacific Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) with a Buy and lowers the price target from $8 to $4.75.

Price Target

Analyst Ratings

BTIG Maintains Buy on Hudson Pacific Properties, Lowers Price Target to $4.75

BMBL

Bumble Says Reducing Size Of Team

ASTS

AST SpaceMobile shares are trading lower after the company announced a registered direct offering to sell 9.45 million shares at $53.22 per share.

Wearable Devices Ltd. (the "Company" or "Wearable Devices") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>, WLDSW))), a technology growth company specializing in artificial intelligence ("AI")-powered touchless sensing wearables, recently announced the expansion of its Large Motor Unit Action Potential Model ("LMM") into new potential markets, such as predictive health monitoring and cognitive state analytics. This development will enable the broadening of bio-signal intelligence applications beyond wearables and will offer businesses and healthcare providers access to real-time physiological insights for monitoring health and wellness conditions.
This strategic expansion into predictive health monitoring aligns with the rising interest in personalized wellness devices. This interest is now demonstrated at the federal level. U.S. Secretary of Health and Human Services, Robert F. Kennedy Jr., has recently advocated for wearable devices to enhance health monitoring and cognitive well-being, underscoring the public and institutional momentum toward real-time data-driven care.
This announcement follows Wearable Devices' recent introduction of LMM as a groundbreaking AI-driven bio-signal platform focused on gesture-based control in extended reality ("XR") and neural interaction with digital devices. The Company's LMM approach to analyzing muscle activity signals will support the expansion into the field of health monitoring, enabling users to enhance their performance across various domains.
From Passive Monitoring to Proactive Intelligence
Unlike traditional bio-sensors that collect data passively, LMM continuously learns and adapts, turning muscle activity signals from the wrist into actionable insights. The technology is now being evaluated in controlled environments for real-world applications, including:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>●</td>
<td>Predictive Health Monitoring&nbsp;- Detecting hidden patterns in muscle activity that may indicate early signs of health conditions before symptoms appear, revolutionizing preventive diagnostics and digital health tracking.</td>
</tr>
<tr>
<td>●</td>
<td>Cognitive State &amp; Performance Analytics&nbsp;- Monitoring focus, fatigue, and stress levels through muscle tone and micro-movements, optimizing work productivity and mental well-being.</td>
</tr>
<tr>
<td>●</td>
<td>Exploring Predictive Analytics -&nbsp;Assessing whether continuous monitoring of neural data can improve AI-driven user behavior predictions.</td>
</tr>
</tbody>
</table>
</figure>
A Platform for Innovation: Opening LMM to Business Partners
Recognizing the transformative potential of bio-signal intelligence, Wearable Devices is intending to make LMM available to enterprises, researchers, and developers. The Company's AI-powered bio-signal data platform is expected to enable businesses to:
&nbsp;

WLDS

Wearable Devices Announces Expansion Of Its Large Motor Unit Action Potential Model Into New Potential Markets Including Predictive Health Monitoring And Cognitive State Analytics

Goldman Sachs analyst Carly Davenport upgrades Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) from Sell to Neutral and raises the price target from $91 to $100.

Upgrades

Goldman Sachs Upgrades Ameren to Neutral, Raises Price Target to $100

Registered Direct Offering
AST SpaceMobile has agreed to sell an aggregate of 9,450,268 shares of its Class A common stock in the Registered Direct Offering at a price of $53.22 per share to holders of the 2032 convertible notes participating in the Repurchase.

Offerings

AST SpaceMobile Announces Registered Direct Offering To Sell 9.45M Shares At $53.22 Each To 2032 Noteholders

Chardan Capital analyst James McIlree maintains Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) with a Buy and maintains $20 price target.

CLSK

Chardan Capital Maintains Buy on Cleanspark, Maintains $20 Price Target

Goldman Sachs analyst Carly Davenport downgrades WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) from Neutral to Sell and lowers the price target from $106 to $100.

Downgrades

Goldman Sachs Downgrades WEC Energy Group to Sell, Lowers Price Target to $100

QXO shares are trading lower after the company announced the pricing of its offering of 89,887,640 shares at $22.25 per share.

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended owning MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>), adding that he has always <a href="https://www.benzinga.com/quote/MP/earnings">liked the stock</a>.
Supporting his view, Baird analyst Ben Kallo, on June 17, maintained MP Materials with an Outperform rating and raised the price target from&nbsp;$30&nbsp;to&nbsp;$38.
When asked about Six Flags Entertainment Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>), he said, &#8220;Don't be interested in it. I don't like the theme parks other than Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>).&#8221;
Supporting his view, Six Flags Entertainment, on May 8, reported worse-than-expected first-quarter sales results.
&#8220;I'm not going to fight anyone who wants to own a nuclear stock. I'm going to bless it even though it's up very, very big,&#8221; Cramer said when asked about BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>).
As per the recent news, BWXT, on June 16, named Kevin McCoy as chief nuclear officer to advance U.S. Navy submarine programs.
Cramer said he is again going to bless Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>). &#8220;It's the kind of company you need to deal with right now — they'll understand all the tariff problems, and they'll help you,&#8221; he added.
Lending support to his choice, Jabil posted third-quarter results on June 17 that exceeded analyst expectations for earnings per share and sales. Jabil also announced an investment of approximately $500 million over the next several years to expand its footprint in the Southeast United States.
Price Action:
<ul class="wp-block-list">
<li>Six Flags shares settled at $30.49 on Tuesday.</li>
<li>MP Materials shares dipped 4.5% to close at $34.91.</li>
<li>BWX Technologies gained 0.2% to settle at $142.31 on Tuesday.</li>
<li>Jabil shares rose 1.7% to close at $211.95.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a></li>
</ul>
Photo: Shutterstock

Long Ideas

BWXT

Why Cramer Thinks Jabil Is The Perfect Stock For A Tariff Storm

CORRECTION: Stryker Ticker Is 'SYK'

Press Releases

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Health Care

Revolution Medicines to Participate in April 2025 Investor Conferences

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Barbara Weber, M.D., Elected to ITM Supervisory Board

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

General

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

Financing

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

Comments

Revolution Medicines

Intérêt court

Revolution Medicines (NASDAQ:RVMD) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL